Navigation Links
Outcomes of steroid therapy following surgery for infants with bile duct disorder
Date:5/3/2014

Among infants who underwent surgery to repair bile ducts that do not drain properly (biliary atresia), the administration of high-dose steroid therapy following surgery did not significantly improve bile drainage after 6 months, although a small clinical benefit could not be excluded, according to a study in the May 7 issue of JAMA, a theme issue on child health. This issue is being released early to coincide with the Pediatric Academic Societies Annual Meeting.

Biliary atresia progresses to end-stage liver disease (cirrhosis) in more than 70 percent of affected children and is the leading indication for pediatric liver transplantation in the world, accounting for about 50 percent of liver transplants in children. Hepatoportoenterostomy (surgery to improve bile drainage) results in successful bile drainage in only about half of patients with biliary atresia treated in the United States, underscoring the need for additional therapies to improve survival without liver transplantation, according to background information in the article. There have been conflicting reports regarding the effectiveness of the use of corticosteroids to improve bile flow following surgery.

Jorge A. Bezerra, M.D., of Cincinnati Children's Hospital Medical Center, Cincinnati, and colleagues randomly assigned 140 infants (average age, 2.3 months) to receive high-dose steroid therapy or placebo following surgery to improve bile drainage.

The researchers found that the proportion of infants with improved bile drainage was not significantly improved by steroids at 6 months following surgery (58.6 percent of steroids group vs 48.6 percent of placebo group). The adjusted absolute risk difference was 8.7 percent.

Survival without liver transplantation at 2 years of age for infants treated with steroids was nearly identical to those who received placebo (58.7 percent vs. 59.4 percent). Serious adverse events were common in both treatment groups (81.4 percent for steroids vs 80.0 percent for placebo); however, infants treated with steroids experienced their first serious adverse events earlier than those receiving placebo.

"Based on the strength of the evidence, the addition of high-dose steroids as an adjuvant [supplemental] treatment for infants with biliary atresia after hepatoportoenterostomy cannot be recommended," the authors write.


'/>"/>

Contact: Nick Miller
nicholas.miller@cchmc.org
513-803-6035
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. New model can predict therapy outcomes in prostate cancer with bone metastasis
2. Drug-eluting stents demonstrate better outcomes after 1 year than bare metal stents
3. USF study finds stem cell combination therapy improves traumatic brain injury outcomes
4. Obesity and diabetes have adverse effects on cancer outcomes
5. Unilateral radiation therapy for advanced stage tonsil cancer results in favorable outcomes
6. UT Southwestern launches Center for Patient-Centered Outcomes Research
7. Extended outcomes from APBI show tumor control, breast cosmesis and minimal late toxicity
8. Good outcomes with staged surgery for epilepsy in children
9. Mayo Clinic study finds standardized protocol and surgery improve mortality outcomes
10. Quality improvement initiative improves asthma outcomes in teens
11. ROI grants $200,000 to evaluate the value of RT and patient outcomes among lung cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2017)... (PRWEB) , ... May 19, 2017 , ... ... RawTrition’s BioEnergy in an upcoming episode of Innovations with Ed Begley, Jr., airing ... RawTrition is the distributor of a clean, organic dietary supplement made from naturally ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Hill Agencies, a family ... entrepreneurs throughout the California Central Valley, is announcing a joint charity initiative with the ... for a local kid’s camp event. , The Boys and Girls Club of Kern ...
(Date:5/19/2017)... ... 2017 , ... SyncDog, Inc. , the leading ISV ... 7th Annual ET6 Exchange (formerly M6 xChange), the Enterprise Transformation Conference. ... expressed purpose is to connect mobile technology end users with industry experts and ...
(Date:5/19/2017)... AZ (PRWEB) , ... May 18, 2017 , ... CloSYS ... known for being non-irritating while extremely helpful for mouth and gum health, which is ... introduced their professionals and customers learned quickly of the powerful ways in which CloSYS ...
(Date:5/18/2017)... , ... May 18, 2017 , ... Dr. Kim Ross ... and educating her community on the link between this condition and serious systemic health ... to severe periodontal disease in Annapolis, MD, and seeking treatment with Dr. ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... 2017  May is Stroke Awareness Month and Omron ... important methods to prevent a stroke: monitor and manage ... Control and Prevention, undetected and uncontrolled hypertension is a ... global leader in personal heart health technology, recently evolved ... attack and stroke and is advancing a national public ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)... 4, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... data solutions, today announced that it is teaming up ... Technologies Limited to lower diabetes healthcare costs in ... card, which is available throughout all provinces and territories ... be eligible for additional savings when shopping for Dario ...
Breaking Medicine Technology: